پایان نامه اثر 8 هفته تمرین استقامتی بر غلظت سرمی واسپین و مقاومت انسولینی زنان چاق و دارای اضافه وزن

منابع انگلیسی

1. Blu¨her M, Rudich A, Klo¨ting N, Golan R, Henkin Y, Rubin E, Schwarzfuchs D, Gepner Y, Stampfer MJ, Fiedler M, Thiery J, Stumvoll M, Shai I. Two patterns of adipokine and other biomarker dynamics in a long term weight loss intervention. Diabetes Care (2011, in press)
2. Blu¨her M. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes. 2009; 117, 241–250
3. Gettins PG. Serpin structure, mechanism, and function. Chem. Rev. 2002; 102, 4751–4804.
4. Chang HM, Park HS, Park CY, et al. Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects. Metabolism 2010; 59: 1276-1281.
5. Aarsland A, Chinkes D, Wolfe RR. (1997). Hepatic and whole-body fat synthesis in humans during carbohydrate overfeeding. American Journal Of Clinical Nutrition. 65(6), 1774-1782.
6. Ahima RS, Flier JS. Leptin. Annu. Rev. Physiol.2000; 62, 413–437.
7. Akbarzadeh S, Nabipour I, Jafari S.M, Movahed A, Motamed N, Assadi M & Hajian N. (2011). Serum visfatin and vaspin levels in normoglycemic first degree relatives of Iranian patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. doi:10.1016/ j.diabres.
8. Akbarzadeh S, Nabipour I, Jafari S.M, Movahed A, Motamed N, Assadi M, Hajian N. Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. (2011) doi:10.1016/ j.diabres.2011.10.004.
9. Aktas B, Yilmaz Y, Eren O, Kurt R, Alahdab YO, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C & Avsar E. (2011). Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism. 60:544-9.
10. Alvin C. Powers, diabetes mellitus. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Larry J, Harrison’s, Principles of Internal Medicin 15th ed. USA: McGraw-Hill; 2001: 2109-2038.
11. American Diabetes Association. Economic consequences of diabetes mellitus in the US in1997.Diabetes Care. 1998; 21: 296-309.
12. Aminot-gilchrist DV, Anderson HD. (2004). Insulin resistance associated cardiovascular disease: potential benefits of CLA. american journal clinic nutration. 1159-1163.
13. Aronne L.J, Wadden T, Isoldi K.K & Woodworth K.A. (2009). When prevention fails: obesity treatment strategies. American Journal Medicine. 122: 24-32.
14. Auernhammer CJ, Melmed S. The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J Clin Invest 2001; 108(12):1735-40.
15. Auguet T, Quintero Y, Riesco D, et al. (2011). New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet. 28; 12(1):60.
16. Aust G, Richter O, Rohm S, Kerner C, Hauss J, Klo¨ting N, Ruschke K, Youn BS, Blu¨her M. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009; 204, 262–266.
17. Azizi Z, Mansoorpoor S, Sabzehvarifard, Asaie S, et al. Effect of Estradiol valerate on pancreatic beta cells resistance in diabetic female rats by streptozotocin. ISMJ 2012. [Article in Press]
18. Bahrami A, Saremi A. [Effect of caloric restriction with or without aerobic training on body composition, blood lipid profile, insulin resistance, and inflammatory marker in middle-age obese /overweight men]. AMUJ. 2011; 14: 11-19.
19. Balen AH, Conway GS, Kaltsas G, Techatraisak K, Manning PJ, West C & Jacobs HS. (1995). Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 10:2107-11.
20. Bashiri J, Rahbaran A, Gholami F, Ahmadizad S, Nikoukheslat S & Moradi A. (2013). The Effect of Acute Exercise on Serum Vaspin Levels and Its Relation to Insulin Sensitivity in Overweight Elderly Men. Zahedan Journal of Research in Medical Sciences.
21. Bays HE, ‘‘Sick fat,’’ metabolic disease, and atherosclerosis. Am. J. Med. 2009; 122, S26–S37.
22. Bee K Tan, Adya R, Farhatullah S, Lewandowsk K.C, O’Hare P, Lehnert H & Randeva H.S. (2008). Omentin-1, a novel adipokine, is decreased in overweight insulinresistant women with polycystic ovary syndrome. Diabetes. 57:801-808.
23. Blu¨her M. The inflammatory process of adipose tissue. Pediatr. Endocrinol. Rev. 2008; 6, 24–31.
24. Blu¨her M. Vaspin in obesity and diabetes: pathophysiologicalnand clinical significance. REV. Endocrine. 2012; 41:176–182.
25. Blüher, M., 2010. Do adipokines link obesity to its related metabolic and cardiovascular diseases? Clinical Lipidology 5:95–107.
26. Bouchard, C. Physical activity and obesity. Champaign IL: Human Kinetics publisher:2000. Pp: 253-254
27. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe.Endocrine. 2010; 37, 11–32 (2010)
28. Brunetti L, C. Di Nisio, L. Recinella, A. Chiavaroli, S. Leone, C. Ferrante, G. Orlando, M. Vacca. (2011). Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides 32, 1866–1871.
29. Bweir S, Al-Jarrah M, Almalty AM, Maayah M, et al. Resistance exercise training lowers HbA1c more than aerobic training in adults with type 2 diabetes. Diabetol Metab Syndr. 2009; 1:27-34.
30. Castan-Laurell I, Dray C, Attane C , Duparc T, Knauf C, Valet P. Apelin, diabetes, and obesity. Endocrine.2011; 40, 1–9.
31. Catalán, V., Gómez-Ambrosi, J., Rodríguez, A., Salvador, J., Frühbeck, G., 2009. Adipokines in the treatment of diabetes mellitus and obesity. Expert Opinion on Pharmacotherapy 10:239–254.
32. Chang H.M, Lee H.J, Park H.S, Kang J.H, Kim K.S, Song Y.S & Jang Y.J. (2010). Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity. 18:2105-2110.
33. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell.1996; 84, 491–495
34. Cho J.K, Han T.K & Kang H.S. (2010). Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. European Journal Applied Physiology. 108:347–353.
35. Church TS, LaMonte MJ, Barlow CE, Blair SN. Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med. 2005; 165: 2114-2120.
36. Cinar N, Gu¨lcelik NE, Aydı´n K, Akı´n S, Usman A, Gu¨rlek A. Serum vaspin levels in hypothyroid patients. Eur. J. Endocrinol. 2011; 165, 563–569
37. Congressionally Established Diabetes Research Working Gourp. Conquering diabetes: a strategic plan for the 21st century; 1999.
38. Cousin B, Munoz O, Andre M, Fontanilles AM, Dani C, Cousin JL, Laharrague P, Casteilla L & Penicaud L. (1999). A role for preadipocytes as macrophage-like cells. FASEB J 13:305-312.
39. DeFronzo RA and Ferrannini F. Insulin resistance. (1991). A mul tifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. American Diabetes Association. 14: 173–194.
40. Devaraj S, Singh U & Jialal I. (2009). The evolving role of C-Reactive protein in atherothrombosis. Clin Chem. 55:229-238.
41. Dimas I, Julia K, Thomas R. (2010). Adipose tissue, inflammation and cardiovascular disease. Rev Assoc Med Bras. 56:116-21.
42. Donnelly JE, Blair SN, Jakicic JM, Manore MM, et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009; 4:459-71.
43. Droste SK, Gesing A, Ulbricht S, Müller MB, et al. Effects of long-term voluntary exercise on the mouse hypothalamic-pituitary-adrenocortical axis. Endocrinology. 2003; 144(7): 3012-3023.
44. Dubnov G, Brzezinski A, Berry EM. Weight control and the management of obesity after menopause: the role of physical activity.The Maturitas. 2003; 44: 89 101.
45. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. (1987). Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperisulinemia. J Clin Endocrinol Metab. 65:499-507.
46. Dunaif A. (1997). Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 18:774-800.
47. El-Mesallamy HO, Kassem DH, El-Demerdash E, et al. (2011). Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism, 60(1):63-70.
48. Enerbäck S. (2009). “The origins of brown adipose tissue”. New England Journal Of Medicine. 360 (19): 2021–2023.
49. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran. Diabetes Care. 2008; 31: 96-98.
50. Febbraio MA, Steensberg A, Starkie RL, McConell GK, Kingwell BA. Skeletal muscle interleukin-6 and tumor necrosis factor-alpha release in healthy subjects and patients with type 2 diabetes at rest and during exercise. Metabolism. 2003; 52(7):939-944.
51. Francisca Lago, Rodolfo Go´mez, Juan J. Go´ mez-Reino, Carlos Dieguez and Oreste Gualillo. (2009). Adipokines as novel modulators of lipid metabolism. 0968-0004.
52. Franco, M., Bilal, U., Orduñez, P., Benet, M., Morejón, A., Caballero, B., et al., 2013. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980-2010: repeated cross sectional surveys and ecological comparison of secular trends. British Medical Journal 346:f1515.
53. Frosig C, Richter EA. (2009). Improved insulin sensitivity after exercise: focus on insulin signaling obesity. 17: 15-20.
54. Gelsinger C, Tschoner A, Kaser S, Ebenbichler CF. (2010). Adipokine update – new molecules, new functions. Wien Med Wochenschr. 160: 377–90.
55. Gesta S, Tseng YH, Kahn CR. (2007). “Developmental origin of fat: tracking obesity to its source”. Cell. 131 (2): 242–256.
56. Ghahramani M, Rohani H, Ghiasi A. (2012). post-resistance exercise response of vaspin adipocytokin and its relation to insulin and glucose levels in overweight woman.11.10.63248
57. Gilman A, Goodman LS, Hardman JG, Limbird LE. Goodman & Gilman’s the pharmacological basis of therapeutics, New York: McGraw-Hill. 2001; ISBN 0-07-135469-7.
58. Goldberg RB. (2009). Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulationin development of diabetes and its complications. Journal Clinical Endocrinol Metab. 94:3171-82.
59. Gomes RJ, Leme JA, de Moura LP, de Araújo MB, et al. Growth factors and glucose homeostasis in diabetic rats: effects of exercise training. Cell Biochem Funct. 2009; 27: 199-204.
60. González. CR, Caminos. JE, Vázquez. MJ, Garcés. MF, Cepeda. LA, Angel. A. et al. (2009). Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. J Physiol. 587.14: 3741–3750.
61. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes. 2003; 52: 2191-2197.
62. Goodwin ML. (2010). Blood glucose regulation during prolonged, submaximal, continuous exercise: a guide for clinicians. Journal Of Diabetes Science Technology. 4(3): 694-705.
63. Goodyear LJ, Kahn BB. (1998). Exercise, glucose transport, and insulin sensitivity. Annual Review Of Medicine. 49: 235-61.
64. Gordon LA, Morrison EY, McGrowder DA. Effect of exercise therapy on lipid profile and oxidative stress indications in patients with type 2 diabetes. BMC Complement Altern Med. 2008; 8: 21-29.
65. Gravholt C H. (2001). “Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. Journal Of Clinical Endocrinology & Metabolism. 86(5): 2085-2089.
66. Guerre-Millo M. (2006). Adipose tissue secretory function: implication in metabolic and cardiovascular complications of obesity. Journal Societe Biologie. 200:37-43.
67. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Natl. Rev. Mol. Cell. Biol. 2008; 9, 367–377.
68. Gulcelik NE, Karakaya J, Gedik A, et al. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol. 2009; 160(1):65-70..
69. Handisurya A, Riedl M, Vila G, Maier C, Clodi M, Prikoszovich T, Ludvik B, Prager G, Luger A, Kautzky-Willer A. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes. Surg. 2010; 20, 198–203.
70. Heydari SH, Nouri Tajer M, Hosseini F, Inanlou M, Shirazi F. Geriatric Family Support And Diabetic Type-2 Glycemic Control. Salmand 2008; 3(8): 53-80. [In Persian].
71. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A.2005; 102(30):10610-10615.
72. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp. Clin. Endocrinol. Diabetes.1999; 107, 119–125.
73. Hu G, Rico-Sanz J, Lakka TA, Tuomilehto J. Exercise, genetics and prevention of type 2 diabetes. Essays Biochem. 2006;42:177-192.
74. Jeffery RW, Wing RR, Sherwood NE, Tate DF. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome? Am J Clin Nutr. 2003; 78: 684-9.
75. Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care. 2007; 30: 744-52.
76. Jeong E, Youn BS, Kim DW, et al. Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J Clin Endocrinol Metab.2010; 95:1869-75.
77. Jung CH, Lee WJ, Hwang JY, et al. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 2011; 413(2):264-9.
78. Kadoglou N.P, Vrabas I.S, Kapelouzou A, Lampropoulos S, Sailer N & Kostakis A. (2011). C.D. Liapis, Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk. Regulatory Peptides. 170:57-61.
79. Kadoglou PE, Vrabas IS, Kapelouzou A , Angelopoulou N. The association of physical activity with novel adipokines in patients with type 2 diabetes. European Journal of Internal Medicine. 2012; 23, 137–142
80. Kang ES, Magkos F, Sienkiewicz E., Mantzoros CS. Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans. Eur. J. Endocrinol. 2011; 164, 911–917.
81. Kang J. (2012). Nutrition and metabolism in sports, exercise and health. USA and Canada: Routledge publisher. 262-9.
82. Kawano K,Hirashima T, Mori S, et al. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992; 41: 1422–1428.
83. Kelley GA, Kelley KS. Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomizedcontrolled trials. Public Health. 2007; 121: 643-55.
84. Kershaw EE, Flier JF. (2004). Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 89:2548-56.
85. Kim SM, Cho GJ, Yannakoulia M, Hwang TG, Kim IH, Park EK, Mantzoros CS. Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations. Metabolism.2011; 60, 1294–1299.
86. Klo¨ting N, Kovacs P, Kern M, Heiker JT, Fasshauer M, Scho¨n MR, Stumvoll M, Beck-Sickinger AG, Blu¨her M. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia. 2011; 54, 1819–1823.
87. Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006; 339(1):430-436.
88. Ko¨rner A, Neef M, Friebe D, Erbs S, Kratzsch J, Dittrich K, Blu¨her S, Kapellen TM, Kovacs P, Stumvoll M, Blu¨her M, Kiess W. Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int. J. Obes. (Lond.). 2011; 35, 578–586.
89. Koiou E, Tziomalos K, Dinas K, Katsikis I, Kalaitzakis E, Delkos D, Kandaraki EA, Panidis D. The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr. J. 2011; 58, 237–246.
90. Kopelman PG. Obesity. In: Hitman AG, Type 2 diabetes Prediction and Prevention, Vol 11. New York. Wiley, 1999.p.3-17.
91. Korner J, Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. Clin Invest 2003; 111:565-570.
92. Kukla M, Zwirska-korczala K, Gabriel A, Waluga M, Warakomska I, Szczygiel B, Berdowska A, Mazur W, Wozniak-Grygiel E & Kryczka W. (2010). Chemerin, vaspin and insulin resistance in chronic hepatitis. C. J. Viral. Hepat. 17:661-667.
93. Kyung Han, T and hyun. k. (2012). Effects of Acute Exercise on Serum Vaspin and Insulin Resistance in Normal and Pre-Diabetes Middle-Aged Women. Exercise Nutrition & Biochemistry. Vol. 16(1), p. 11.
94. C.J, Kyung. H.T and Kang. H.S. (2010). Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. (Report). European Journal of Applied Physiology. Jan, Vol.108 (1), p.347 (7).
95. Larrjani B. Proceeding of Congress of Cardiology and Surgery & Diabetes Congress. 2003; Nov 27-29; Tehran, Iran .
96. Lee JA, Park HS, Song YS, Jang YJ, Kim JH, Lee YJ, Heo YS. Relationship between vaspin gene expression and abdominal fat distribution of Korean women. Endocr. J. 2011; 8, 639–646.
97. Lee MK, Jekal Y, Im JA, Kim E, Lee SH, Park JH, u SH, Chung KM, Lee HC, Oh EG, Kim SH, Jeon JY. Reduced serum vaspin concentrations in obese children following short-term intensive lifestyle modification. Clin Chim Acta. 2009; 411(5-6):381-385.
98. Lehr, S., Hartwig, S., Lamers, D., Famulla, S., Muller, S., Hanisch, F.G., et al., 2012. Identification and validation of novel adipokines released from primary human adipocytes. Molecular and Cellular Proteomics 11 (M111):010504.
99. Lehringer AL, Nelson DL,Cox MM. Principles of biochemistry.2nd ed. New York:Worth publishers; 1993;606,761.
100. Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T, Takahashi T. (2008). A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin) and obesity. Journal International Medicine Research. 36:625-9.
101. Loeffelholz C, Mohlig M, Arafat A.M, Isken F, Spranger J, Mai K, Randeva H.S, Pfeiffer A.F & Weickert M.O. (2010). Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. European Journal Endocrinol. 162:507–513.
102. MacDougald OA & Burant CF. (2007). The rapidly expanding family of adipokines. Cell Metabolism. 6:159-61.
103. Maiorana A, O’Driscoll G, Goodman C, et al. Combined and resistance exercise improve glycemic control and fitness in type 2 diabetes. Diabetes Res Clin Pract. 2002; 56: 115-23.
104. Martos-Moreno GA, Kratzsch J, Ko¨rner A, Barrios V, Hawkins F, Kiess W, Argente J. Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int. J. Obes. (Lond). 2011; 35, 1355–1362.
105. Mauras N, Del Giorno C, Kollman C, Bird K, Morgan M, Sweeten S, Balagopal P, Damaso L. (2010). Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. Journal Clinical Endocrinol Metab. 95:1060-1068.
106. McGavock J, Sellers E, Dean H. Physical activity for the prevention and management of youth-onset type 2 diabetes mellitus: focus on cardiovascular complications. Diab Vasc Dis Res. 2007; 4: 305-10.
107. Mourad JJ, Le Jeune S. Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens Suppl. 2008; 26: 7-13.
108. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A & Otsuki M. (2004). Insulin resistance and insulin secretion in chronic hepatitis C virus infection. Journal of Hepatology. 41:132-8.
109. Neitzel JJ. Enzyme Catalysis. (2010). The Serine Proteases. Nature Education. 3:21.
110. Nestler JE. (2008). Metformin for the treatment of the polycystic ovary syndrome. New England Journal Medicine. 358:47-54.
111. Oberbach A, Kirsch K, Lehmann S, Schlichting N, Fasshauer M, Zarse K, Stumvoll M, Ristow M, Blu¨her M, Kovacs P. Serum vaspin concentrations are decreased after exercise-induced oxidative stress. Obes. Facts. 2010; 3, 328–331.
112. Otero M, Lago R, Casanueva FF, Dieguez C, Gomez-Reino JJ & Gualillo O. (2005). Leptin, from fat to inflammation: old questions and new insights. FEBS Letters. 579:295-301.
113. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H & Matsuzawa Y. (2003). Reciprocal association of C-Reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 107:671-674.
114. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007; 30: 1374-83.
115. Potempa J, Korzus E & Travis J. (1994). The Serpin Superfamily of Proteinase Inhibitors: Structure, Function, and Regulation. Journal Biological Chemistry. 269:15957-60.
116. Poulos SP, Hausman DB, Hausman GJ. (2010). The development and endocrine functions of adipose tissue. Mol. Cell. Endocrinol. 323(1): 20–34.
117. Praet SF, Manders RJ, Lieverse AG, Kuipers H, Stehouwer CD, Keizer HA. et al. Influence of Acute Exercise on Hyperglycemia in Insulin- Treated Type 2 Diabetes. Medicine & science in Sports & Exercise. 2006; 38: 2037-2044.
118. Pruchnic R, Katsiaras A, He J, Kelley DE, et al. Exercise training increases intramyocellular lipid and oxidative capacity in older adults. Am J Physiol Endocrinol Metab. 2004; 287: 857-62.
119. Rabe K, et al. (2008). Adipokines and insulin resistance. Mol. Med. 14:741–51.
120. Ravussin, E., Gautier, J.F., 1999. Metabolic predictors of weight gain. International Journal of Obesity and Related Metabolic Disorders 23 (Suppl. 1):S37–S41.
121. Rawal LB, Tapp RJ, Williams ED, Chan C, et al. Prevention of type 2 diabetes and its complications in developing countries: A Review. Int J Behav Med.2011; 4: 18-28.
122. Saremi A, Moslehabadi M, Parastesh M. [Effects of Twelve-week Strength Training on Serum Chemerin, TNF-α and CRP Level in Subjects with the Metabolic Syndrome].IJEM. 2011; 12: 536-43.
123. Seeger J, Ziegelmeier M, Bachmann A, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab. 2008; 93(1):247-251.
124. Shai I, Schwarzfuchs D, Henkin Y, Shahar D.R, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi- Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler G.M, Bluher M, Stumvoll M & Stampfer M.J. (2008). Weight loss with a lowcarbohydrate, Mediterranean, or low-fat diet. New England Journal Medicine. 359:229–241.
125. Shavandi N, Saremi A, Ghorbani A. [Effect of aerobic training on resistin levels and insulin resistance in adults with type 2 diabetes]. Research on Sport Science. In press.
126. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K & Matsuzawa Y. (1996). Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Medicine. 2(7):800-803.
127. Sigal RJ, Kenny GP, Boulé NG, Wells GA, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med. 2007; 147:357-3 69.
128. Sjöström, L., Narbro, K., Sjöström, C.D., Karason, K., Larsson, B., Wedel, H., et al., 2007. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. New England Journal of Medicine 357:741–752.
129. Steinmetz A. Treatment of diabetic dislipoproteinemia. Exp Clin Endol Diabetes. 2003; 111:239-245.
130. Stephan S, Annette G & Sickinger B. (2012). Chemerin and vaspin: possible targets to treat obesity? ChemMedChem. 8(4):549-559.
131. Stewart KJ. Role of exercise training on cardiovascular disease in persons who have type 2 diabetes and hypertension. Cardiol Clin. 2004; 22: 569-86.
132. Suh SH, Paik IY, Jacobs K. (2007). Regulation of blood glucose homeostasis during prolonged exercise. Mol Cells. 23:272-9.
133. Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract. 2009; 84(3):325-328
134. Suwala A, et al. (2012). serum concentrations of chemerin, omentin-1 and vaspin in girls with anorexia nervosa. 29 P1295.
135. Tan B.L, Heutling D, Chen J, Farhatullah S, Adya R, Keay S.D, Kennedy C.R, Lehnert H & Randeva H.S. (2008). Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes. 57:1501-1507.
136. Thomas GN, Jiang CQ, Taheri S, Xiao ZH, et al. A systematic review of lifestyle modification and glucose intolerance in the prevention of type 2 diabetes. Curr Diabetes Rev. 2010; 6: 378-387.
137. To¨njes A, Fasshauer M, Kratzsch J, Stumvoll M, Blu¨her M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS ONE 5, e13911 (2010)
138. Toulza E, Mattiuzzo NR, Galliano MF, Jonca N, Dossat C, Jacob D, Daruvar D.E, Wincker P, Serre G & Guerrin M. (2007). Large-scale identification of human genes implicated in epidermal barrier function. Genome Biology. 8:R107.
139. Trujillo ME & Scherer PE. (2000). Adipose tissue-derived factors: impact on health and disease. Endocrine Reviews. 627:762-78.
140. Trujillo ME, Scherer PE. Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 2005; 257, 167–175.
141. Van Gaal LF, Mertens IL, DeBlock CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444, 875–880
142. Vazquez-Vela, M.E, Torres N & Tovar AR. (2008). White adipose tissue as endocrine organ and its role in obesity. Archives Medicine Research. 39:715-728.
143. Verity LS. Diabetes Mellitus and Exercise. In: Kaminsky LA. ACSMُ s Resource Manual for Guidelines for Exercise Testing and Prescription. 5th edition. Philadelphia, Lippincott Williams & Wilkins. 2006 p: 470-479.
144. von Loeffelholz C, Mo¨hlig M, Arafat AM, Isken F, Spranger J, Mai K, Randeva HS, Pfeiffer HS, Weickert MO. Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur. J. Endocrinol. 2010;162, 507–513
145. Wada J. (2008). Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin. Investig. Drugs. 17:327–33.
146. Wadden, T.A., 1993. Treatment of obesity by moderate and severe caloric restriction: results of clinical research trails. Annals of Internal Medicine 229:688–693.
147. Wajchenberg BL. (2000). Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome. Endocrine Reviews. 21:697-738.
148. Wang YM, Wang WP, Wang LP, Lü QH, Zhou XH. Calorie control increased vaspin levels of serum and periepididymal adipose tissue in diet-induced obese rats in association with serum free fatty acid and tumor necrosis factor alpha. Chin Med J (Engl). 2010; 123(7):936-941.
149. Wannamethee SG, Lowe GD, Rumley A, Lynne CL, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007; 30: 1200–1205.
150. Williams R, Tuomilehto J, Bjork S. The Economics of Diabetes Care: an international perspective. London: Blackwell Science; 2000.
151. wilmore j. H. , and costil, D. L. physiology of sport and exercise. Champaign IL: human kinetics pu ication; 1994
152. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy ansity. Nat Med. 2001; 7(8):941-946     .
153. Yamawaki H. Vascular Effects of Novel Adipocytokines: Focus on Vascular Contractility and Inflammatory Responses. Biol Pharm Bull. 2011; 34: 307-310.
154. Ye Y, Hou XH, Pan XP, et al. (2009). Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J, 122(21):2530-3.
155. Yilmaz Y, Kurt R, Gurdal A, Alahdab Y.O, Yonal O, Senates E, Polat N, Eren F, Imeryuz N & Oflaz H. (2011). Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis. 217:125–129.
156. Youn BS, Kloting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008; 57: 372-377.
157. KJ, Sung Kim. E, Justin. Y and Jekal Y. (2011). Improved Insulin Resistance, Adiponectin and Liver Enzymes without Change in Plasma Vaspin Level after 12 Weeks of Exercise Training among Obese Male Adolescents. The Korean Journal of Obesity. Vol. 20, No. 3.
158. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature.1994; 372, 425–432.
159. Zierath JR, Krook A, and Wallberg-Henriksson H. (2000). Insulin action and insulin resistance in human skeletal muscle. Diabetologia: 821–835.